The board of directors of Nasdaq-listed company Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset
According to PR Newswire, Anixa Biosciences, Inc. (NASDAQ: ANIX), a Nasdaq-listed company in the United States, announced that its board of directors has approved the purchase of Bitcoin as a treasury reserve asset with the aim of diversifying the company's assets and enabling Anixa to benefit from the potential long-term value of digital assets. It is reported that Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: Multiple tokens experience a surge followed by a pullback, EGLD hits a new weekly low
Analysis: Ethereum has held its support level, Bitcoin is expected to rebound to $100,000
An Ethereum OG address deposited 18,000 $ETH worth $54.78 million to an exchange.
Circle mints 1 billion USDC on Solana network within 24 hours
Trending news
MoreCrypto prices
More
